Literature DB >> 32493070

Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.

Feng Zhou1,2,3,4, Ye-Mao Liu2,4, Jing Xie2,4, Haomiao Li2,4, Fang Lei2, Huilin Yang2, Juan-Juan Qin2,4, Jingjing Cai5, Xiao-Jing Zhang2,4, Bin Wu2,4, Meng Xia2, Da Xiang2, Chengzhang Yang2, Xinliang Ma6, Qingbo Xu7, Zhigang Lu8, Haofeng Lu9, Xigang Xia10, Daihong Wang11, Xiaofeng Liao12, Gang Peng13, Jun Yang14, Xiaodong Huang15, Bing-Hong Zhang16, Yufeng Yuan17, Xiang Wei18, Peter P Liu19, Yibin Wang20, Peng Zhang1,2, Zhi-Gang She2,4, Jiahong Xia21, Hongliang Li1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32493070     DOI： 10.1161/HYPERTENSIONAHA.120.15622

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  26 in total

Review 1.  Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.

Authors:  Jordan Loader; Frances C Taylor; Erik Lampa; Johan Sundström
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

2.  Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review.

Authors:  José Pedro L Nunes
Journal:  Porto Biomed J       Date:  2020-11-11

3.  Androgens, the kidney, and COVID-19: an opportunity for translational research.

Authors:  Licy L Yanes Cardozo; Samar Rezq; Jacob E Pruett; Damian G Romero
Journal:  Am J Physiol Renal Physiol       Date:  2021-01-19

4.  Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review.

Authors:  Nathalie Gault; Marina Esposito-Farèse; Matthieu Revest; Jocelyn Inamo; André Cabié; Élisabeth Polard; Jean-Sébastien Hulot; Jade Ghosn; Catherine Chirouze; Laurène Deconinck; Jean-Luc Diehl; Julien Poissy; Olivier Epaulard; Benjamin Lefèvre; Lionel Piroth; Etienne De Montmollin; Eric Oziol; Manuel Etienne; Cédric Laouénan; Patrick Rossignol; Dominique Costagliola; Emmanuelle Vidal-Petiot
Journal:  Fundam Clin Pharmacol       Date:  2021-05-16       Impact factor: 2.747

Review 5.  Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19.

Authors:  Branka Miličić Stanić; Sydney Maddox; Aline M A de Souza; Xie Wu; Danial Mehranfard; Hong Ji; Robert C Speth; Kathryn Sandberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-13       Impact factor: 3.210

Review 6.  Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Leanne Groban
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

7.  Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.

Authors:  Lu Ren; Shandong Yu; Wilson Xu; James L Overton; Nipavan Chiamvimonvat; Phung N Thai
Journal:  J Cardiol       Date:  2020-11-02       Impact factor: 3.159

8.  Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.

Authors:  Feifei Yan; Fengming Huang; Jun Xu; Penghui Yang; Yuhao Qin; Jingjun Lv; Shaogeng Zhang; Lu Ye; Ming Gong; Zhibo Liu; Jie Wei; Tuxiu Xie; Kai-Feng Xu; George F Gao; Fu-Sheng Wang; Lin Cai; Chengyu Jiang
Journal:  Cell Discov       Date:  2020-10-29       Impact factor: 10.849

9.  Diabetes and Covid-19: Clinical implications and novel management strategies.

Authors:  R D'Arcy; C H Courtney
Journal:  Ulster Med J       Date:  2021-07-08

Review 10.  Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.

Authors:  Chang Chu; Shufei Zeng; Ahmed A Hasan; Carl-Friedrich Hocher; Bernhard K Krämer; Berthold Hocher
Journal:  Br J Clin Pharmacol       Date:  2020-12-18       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.